ArticleCost effectiveness and resource allocation : C/E2025
Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile.
Tomás Abbot et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.